Purpose: The retina is highly metabolically active, suggesting that metabolic 25 dysfunction could underlie many retinal degenerative diseases. Nicotinamide 26 adenine dinucleotide (NAD + ) is a cofactor and a co-substrate in several cellular 27 energetic metabolic pathways. Maintaining NAD + levels may be therapeutic in 28 retinal disease since retinal NAD + levels decline with age and during retinal 29 damage or degeneration. The purpose of this study was to investigate whether 30 systemic treatment with nicotinamide riboside (NR), a NAD + precursor, is 31 protective in disparate models of retinal damage or degeneration. 32 33 Methods: Three mouse models of retinal degeneration were tested: an albino 34 mouse model of light-induced retinal degeneration (LIRD) and two models of 35 retinitis pigmentosa (RP), including a mouse line deficient in interphotoreceptor 36 binding protein (IRBP) gene expression (IRBP KO), and a naturally-occuring 37 cGMP phosphodiesterase 6b mutant mouse model of RP (the Pde6b rd10 mouse). 38 Mice were intraperitoneally (IP) injected with PBS or NR at various times relative 39 to damage or degeneration onset. One to two weeks later, retinal function was 40 assessed by electroretinograms (ERGs) and retinal morphology was assessed 41 by optical coherence tomography (OCT). Afterwards, retina sections were H&E 42 stained for morphological analysis or by terminal deoxynucleiotidyl transferase 43 dUTP nick and labeling (TUNEL). Retinal NAD + /NADH levels were enzymatically 44 assayed. 45 46 3 Results: The retinal degeneration models exhibited significantly suppressed 47 retinal function, and where examined, severely disrupted photoreceptor cell layer 48 and significantly decreased numbers of nuclei and increased accumulation of 49 DNA breaks as measured by TUNEL-labeled cells in the outer nuclear layer 50 (ONL). These effects were prevented by various NR treatment regimens. IP 51 treatment with NR also resulted in increased levels of NAD + in retina. 52 53 Conclusions: This is the first study to report protective effects of NR treatment in 54 mouse models of retinal degeneration. The positive outcomes in several models, 55 coupled with human tolerance to NR dosing, suggest that maintaining retinal 56 NAD + via systemic NR treatment should be further explored for clinical relevance. 57 58 59 60 61 62 63 64 65 66 67 68 0.00039 0.00374 0.058 0.961 25.3 Flash intensity (cd s/m 2 ) Flash intensity (cd s/m 2 ) Flash intensity (cd*s/m 2 ) * * * * 0.00039 0.00374 0.058 0.961 25.3 Flash intensity (cd s/m 2 ) Flash intensity (cd s/m 2 )
Introduction 69
Retinal diseases are a leading cause of blindness globally, accounting for 70 more than 25% of all vision impairment (over 55 million people). 1 Macular 71 degenerations such as age-related macular degeneration (AMD), inherited retinal 72 degenerations such as retinitis pigmentosa (RP), and several other retinopathies, 73 syndromes, and dystrophies are linked to mutations in over 300 different genes 74 or loci (Retnet; sph.uth.edu/retnet/disease.htm; update 10/29/2019). In addition 75 to heterogeneous heritable risk factors, several retinal diseases such as AMD 76 have strong environmental risk factors such as smoking, or the case of retinal 77 detachments with degenerative outcome, extreme myopia. [2] [3] [4] [5] Although treatment 78 strategies based on specific genetic mutations, risk factors, or combinations 79 thereof are being developed (one gene therapy study has already entered the 80 clinic 6 ), approaches with targets that are common to many diseases may have 81 greater impact. 82
Though of varied etiology, the outcome that is common to retinal 83 degenerative diseases is the progressive loss of rod and cone photoreceptor 84 cells and retinal pigment epithelial (RPE) cells. The retina is the most 85 metabolically demanding tissue in the body, and experiences significant, 86 persistent oxidative stress arising from its primary function, visual transduction. 7, 8 87 Photoreceptor cells in particular are highly metabolically active as their normal 88 function includes maintenance of the "dark current" and continuous production of 89 proteins that support their specialized function, 8 many of which are lost daily due 90 to outer segment disc shedding. 9 Because of this, photoreceptors are thought to 91 be especially sensitive to dysregulation of bioenergetic metabolism. [10] [11] [12] Indeed, 92 genetic mutations that degrade photoreceptor bioenergetic metabolism cause 93 blindness, including mutations of Krebs cycle enzymes that cause forms of RP 13 94 and mutations in mitochondrial DNA (mtDNA) that cause Leber Hereditary Optic 95 Neuropathy (LHON). 14 Also, as photoreceptor and RPE cells exist within a 96 metabolic symbiosis, 15 functional compromise in one cell type may negatively 97 affect function in the other. 10 Thus, targeting metabolic pathways of 98 photoreceptor or RPE cells may be therapeutic across a variety of retinal 99 diseases. 100
Nicotinamide adenine dinucleotide (NAD + ) is a cofactor in glycolysis and 101
the Krebs cycle and a co-substrate for NAD + -consuming enzymes. 8, 16 NAD + 102 levels decline with age and in neurodegeneration, possibly in response to 103 increased activity of NAD + -consuming enzymes involved in DNA repair, such as 104 poly (ADP-ribose) polymerase (PARP). 16 Maintenance of NAD + levels is critical to 105 retinal health. Mutations in nicotinamide mononucleotide adenylyltransferase-1 106 (NMNAT1), a NAD + salvage pathway enzyme, causes Leber Congenital 107
Amaurosis Type 9 (LCA9). [17] [18] [19] Experimentally inhibiting nicotinamide 108 phosphoribosyltransferase (NAMPT), a key enzyme in a NAD + salvage 109 biosynthesis pathway, with pharmacological agents causes retinal 110 degeneration. 20 In a seminal series of experiments, Apte and colleagues 111 established the importance of NAD + in retinal health and the role of NAD + 112 deficiency in retinal degeneration. 8 They found that retinal NAD + levels decline in 113 models of retinal degeneration and that mice made deficient in NAMPT have 114 diminished retinal NAD + and develop retinal degeneration. 21 Further, they 115 6 demonstrated that systemic treatment with the NAD + precursor nicotinamide 116 mononucleotide (NMN) was protective in mouse models of retinal 117 degeneration. 21 Similarly, John and colleagues have demonstrated that NAD + is 118 critical to retinal ganglion cell (RGC) health, that NAD + levels decline in models of 119 glaucoma, and that treatment of these models with NAM maintains or increases 120 NAD + in RGCs via the NAMPT pathway, and that this protects function and optic 121 nerve morphology. 22, 23 122 Brenner and colleagues discovered an alternative NAD + salvage 123 biosynthesis pathway in which nicotinamide riboside (NR), a form of vitamin B3 124 that is found in milk and other foods, 24, 25 can be taken up from oral dosing in 125 humans. 26 NR enters cells through nucleotide transporters and is then converted 126 to NMN then to NAD + by NR kinases (NMRK1 and NMRK2) and NMNAT 127 isozymes. 27, 28 They and others find that administration of NR to rodents prevents 128 cognitive decline and amyloid-beta peptide aggregation, 29 prevents noise-129 induced neurite degeneration and hearing loss, 30 protects in several models of 130 neuropathies, 31, 32 and protects against excitotoxicity-induced or axotomy-131 induced axonal degeneration. 33, 34 The NMRK kinases are expressed in many 132 neuronal subtypes, and may be upregulated following neuronal injury or during 133 extreme energetic stress. 16 in Results) using an injection volume of 10 μl of solution per gram of mouse body 197 weight in accordance with in vivo rodent experiments of Yen et al. 49 For LIRD 198 experiments, two injections were administered before a toxic light exposure. One 199 injection was performed the day before (at 4 pm), and the other injection was 200 performed at 9 am the morning of light insult. Toxic light exposure was from 10 201 am to 2 pm. The IRBP KO mice received treatment 5 days per week from P18 to 202 P33. rd10 mice were injected 5 days per week from P6 to P27. Injections from 203 P6-P14 were subcutaneous, and from P15-P27 were IP. 204 205 Electroretinograms (ERG) -The complete ERG protocol was previously 206 detailed. 50 Briefly, mice were dark-adapted overnight. In preparation for ERGs, 207 mice were anesthetized with IP injections of ketamine (10 mg/ml: AmTech Group 208
Inc.) and xylazine (100 mg/ml; AKORN Animal Health, Lake Forest, IL). 50 209 Proparacaine (1%; AKORN, Lake Forest, IL) and tropicamide (1%; AKORN, Lake 210 Systems Inc., San Jose, CA). The number of pixels was converted into 238 micrometers by multiplying by the micrometers/pixel conversion factor (1.3 239 microns = 1 pixel). Immediately after imaging on the Micron IV system, a rigid 240 contact lens was placed on the eye (Back Optic Zone Radius: 1.7 mm, diameter: 241 3.2 mm, power: PLANO) and blue autofluorescence imaging at the layer of the 242 photoreceptor-RPE interface was conducted using the Heidelberg Spectralis 243 HRA+OCT instrument. During imaging and afterwards through anesthesia 244 recovery, mice were kept on a water circulating heat pad set to 39 °C to maintain 245 body temperature. 246 247
Histology and Morphometrics 248
The Balb/c mice were sacrificed the same day after in-vivo measurments. We 249 followed the recommendations of Howland and Howland 52 for nomenclature of 250 axes and planes in the mouse eye, as indicated in Figure 1 . Histologic and 251 morphometric procedures followed standard techniques. 46, 53 Eyes were 252 dehydrated, embedded in paraffin, and sectioned through the sagittal plane on a 253 microtome at 5 µm increments. Sections were cut on a vertical (sagittal) plane 254 through the optic nerve head (ONH) and the center of the cornea to ensure that 255 consistent regions were examined between animals. Slides were de-paraffinized 256 across five Coplin jars with 100 ml of xylene for two minutes each, consecutively. 257
Then slides were rehydrated in a series of 100 ml ethanol solutions for two 258 minutes each: 100%, 90%, 80%, 70%, 60%, 50%. Slides were immersed in PBS 259 for five minutes twice. After rehydration, a TUNEL assay was performed on 260 some sections according to the protocol for the DeadEnd Fluorometric TUNEL Levels of NAD + in retina homogenates were measured using a commercially 272 available kit by following manufacturer's instructions (Abcam; ab. 65348; #Lot: 273 GR3226737-3; San Francisco, CA). In brief, retina samples were homogenized in 274 extraction buffer. Extracted samples were separated in two aliquots. One was 275 used to measure total NAD (NADt). The other was heated to 60℃ for 30 minutes 276 to convert NAD + to NADH. Samples were placed in a 96-well plate. Then, NADH 277 developer was added into each well and incubated at room temperature for 1-4 278 hours. The plate was placed into a hybrid reader and read every half hour at OD 279 450nm while the color was still developing. We used the 2-hour data, at which 280 the reaction was well developed. NADt and NADH concentration was quantified 281 comparing with NADH standard curve data. In the end, NAD + was calculated with 282 the equation NAD + =NADT-NADH. 283
284
Statistical Analyses -Statistical analyses were conducted using Prism 8.1.1 285 Software (GraphPad Software Inc. La Jolla, CA, USA). One-way ANOVA with 286
Tukey's post-hoc test, two-way ANOVA with Sidak's post-hoc test, and Student's 287 t-tests were performed for ERG, biochemical, and morphometric data. Tukey 288 post-hoc test is considered to be more powerful in comparing every mean with 289 every other mean, and so is most appropriate for our use of the one-way 290 ANOVA. Sidak's test is more generalized, allowing for comparisons of just 291 subsets of means, and thus recommended for our use of the two-way ANOVA. 292
For all analyses, results were considered statistically significant if p < 0.05. All 293 graphs display data as mean ± SEM. The stated n is the number of animals or 294 individual eye used in each group. Representative ERG waveforms of one eye of a single mouse from each 303 treatment group are shown in Fig. 2 . This functional loss was entirely prevented 304 in mice treated with NR ( Fig. 3A, 3B ). Functional loss was diminished 305 significantly, but not entirely, in the two genetic mouse models of RP. The IRBP 306 KO mouse degeneration starts around P24 with a burst of apoptosis in the outer 307 nuclear layer, followed by a very gradual loss of photoreceptor cells over the 308 lifespan of the animals. 40 This gradual loss is accompanied by a gradual decline 309 of ERG waveform amplitudes. 54 Scotopic and photopic ERG a-and b-wave 310 amplitudes were greater following daily NR versus PBS injections (Fig. 4) . The 311 rd10 mouse has an early onset and rapid photoreceptor degeneration due to a 312 mutation in the beta subunit of rod phosphodiesterase, with significant 313 morphological and functional losses apparent at P16 that are nearly complete by 314 P30. 42, 50 Daily IP injections of NR significantly preserved scotopic ERG b-wave 315 amplitudes and photopic ERG a-and b-wave amplitudes ( Fig 5) . This protective 316 effect persisted at P38, 10 days after treatment had been halted ( Fig 6) . These 317 data suggest that NR treatment protects against of retinal damage and 318 degeneration. 319 320
NR treatment preserves retinal morphology in LIRD mouse 321
As imaged in vivo by fundus photography and SD-OCT one week after 322 degeneration induction, the retinas of LIRD mice treated with PBS exhibited 323 significant damage (Fig. 7) . The representative fundus image of Fig. 7A shows 324 the region being measured. Corresponding SD-OCT images show considerable 325 thinning of the photoreceptor layer that is prevented by NR treatment (Fig. 7B) . 326
Quantification of total retina and photoreceptor layer thicknesses show that mice 327 undergoing LIRD had significantly thinner retinas compared to non-induced mice, 328 largely due to nearly complete loss of the photoreceptor layer. This was entirely 329 prevented with NR treatment (Fig. 7C, 7D) . was prevented in mice treated with NR ( Fig. 8C and Fig. S1 ). Quantification of 338 ONL nuclei counts across retinal sections confirmed significant losses due to 339 degeneration in PBS-treated mice and confirmed nearly-complete preservation, 340 in NR-treated mice ( Fig. 8D and Fig. S1 ). 341 342 NR treatment prevents accumulation of TUNEL signal in photoreceptor 343
cells of LIRD mice 344
Paraffin-embedded ocular sections from mice euthanized a week after toxic light 345 induction were stained for TUNEL and DAPI to label nuclei that contained 346 double-stranded DNA breaks (a marker of programmed cell death [apoptosis] or 347 other forms of cell death). 55 ONL TUNEL signal was high in retinas from LIRD 348 mice treated with PBS compared to retinas from uninduced mice (Fig. 9A, 9B  349 and Fig. S2 ). Induced mice treated with NR exhibited significantly less TUNEL 350 signal ( Fig. 9C and Fig. S2 ). These data suggest that NR treatment diminished or 351 delayed apoptosis in photoreceptor cells. autofluorescent spots at the level of the subretinal space in vivo (Fig. 10A) . In 362 eyes of induced mice treated with PBS, numerous and widespread 363 autofluorescent spots were observed (Fig. 10B ). This was prevented in mice 364 treated with NR, which exhibited fewer autofluorescent spots (Fig. 10C) , similar 365 in number and pattern to the uninduced group, confirmed by statistical testing on 366 counts of these spots across several autofluorescent fundus images (Fig. 10D) . 367
These data suggest that LIRD leads to an inflammatory response that is largely 368 prevented by NR treatment. 369
370

NR elevates retinal NAD + levels in mice 371
NR is a NAD + precursor that when given systemically increases NAD + levels in 372 many tissues, including CNS structures, 29, 35, 36 and its protective effects are 373 ascribed in part to local NAD + increases in target tissue. 30-32, 34, 36 As an initial test 374 of whether this may be the case in NR-induced retinal neuroprotection, we used 375
C57Bl/6J mice to test whether NR treatment could increase NAD + levels in retina. 376
We IP-injected mice with either NR or PBS daily for 5 days. One hour after the 377 last treatment, retinas were harvested and assayed for NAD + /NADH content, 378 revealing that NR treatment increased retinal NAD + (Fig 11A. ) and NAD + /NADH 379 ratio ( Fig 11B) compared to the PBS-treated group. 380 381
Discussion 382
In this study, we found that systemic treatment with NR protected photoreceptors 383 from toxic light damage and delayed inherited retinal degeneration. NR has been 384
shown to be protective in many models of neurodegenerative diseases, like 385
Parkinson's disease 35 and Alzheimer's disease. 29 Our study is the first to 386 demonstrate NR's protective effects in retinal degeneration models. 387
388
Light-induced retinal damage is an acute model of retinal degeneration with a 389 well-described oxidative stress response. 61 We assessed by ERG the efficacy of 390 NR treatment in preserving phoreceptor function in mice undergoing LIRD (Fig.  391 3). Remarkably, just two NR IP injections completely preserved scotopic a-and 392 b-wave amplitudes. In vivo OCT imaging and fundus imaging showed that 393 systemic NR treatment protected photoreceptors and whole retina from 394 degeneration (Fig 7) . Postmortem H&E staining provided more detailed 395 information on retinal morphology, indicating that NR treatment protected retinal 396 structure, both inferior and superior (Fig. 8) . Retinas of mice undergoing LIRD 397 exhibited marked TUNEL staining, especially in the ONL, suggesting massive 398 apoptosis of photoreceptor cells (Fig. 9 , compare Panel A with Panel B). NR 399 treatment largely prevented this, suggesting that apoptosis was suppressed ( Fig  400   9 ). retina. 66, 67 The present data indicate that NR treatment prevented the 407 appearance of these autofluorescing entities (Fig 10) , and thus, may be 408 preventing retinal inflammation, possibly indirectly by partially preventing early 409 rod photoreceptor injury, or more directly by some as-yet undefined action. 410
411
Although the LIRD mouse model of retinal degeneration has been extremely 412 valuable in increasing our understanding of photoreceptor and retinal 413 degeneration, 37, 68, 69 it is a damage model and not a disease model. The rd10 414 mouse and the IRBP KO mouse are considered models of arRP. 42, 46, 47, 50, 70-76 415 We found that retinal NR protection extends to these two arRP models (Fig 4-6) , 416 with significant increases of ERG amplitudes well after photoreceptor 417 degeneration onset and retinal function loss in untreated cohorts. 42, 46, 47, 50, 70-74, 418 76 The NR-induced increase in ERG mean amplitudes in IRBP KO mice, though 419 significant (Fig. 4) , was modest most likely because retinal function has not yet 420 declined dramatically at this early stage in the degeneration. 40, 54 The NR-induced 421 increases in mean amplitudes of scotopic b-waves and photopic a-and b-waves 422 in P28 rd10 mice were more dramatic and persisted at least 10 days after 423 injections were halted (Figs. 5 and 6), demonstrating that NR treatment is 424 capable of preserving cone photoreceptor and inner retinal function even at a 425 stage at which extensive degeneration and function loss otherwise occurs. 42, 72, 75 426 Rod photoreceptor function was not protected, unsurprising given that the 427 mutation underlying the degeneration is in a rod-specific phototransduction 428 gene. 42, 72 Overall, it appears that systemic treatment with NR protects against 429 both retinal damage and disease. 430 431 Photoreceptors and RPE have high metabolic demands. 15 It may be that the 432 observed increase in NAD + and NAD + /NADH ratio following NR treatment ( Fig.  433 11) allowed increased retinal metabolic capacity that contributed to protection. 77 434
Recent work investigating the effects of NR in yeast and mammals established 435 that its metabolic pathway involves kinases NMRK1 and NMRK2, which were 436 20 first described by Brenner and colleagues in 2004. 27 Apte and collegues 437 demonstrated that an intact nicotinamide-NAMPT-NAD+ pathway is requisite for 438 retinal health, but whether the same holds true for an NR-NMRK1/2-NAD+ 439 pathway has not been explored. Additionally, it may be useful to compare the 440 efficacy and potency between NR and nicotinamide treatment in retinal 441 degeneration. Nicotinamide treatment has been well-investigated in 442 neurodegenerative diseases, in mouse glaucoma models, 22, 23, 78 79 and in a rat 443 LIRD model, 80 but has yet to be test in a mouse retinal degeneration model. 444
445
In summary, this is the first study to demonstrate that systemic treatment with 446 nicotinamide riboside is protective for photoreceptors undergoing stress in 447 damage and in genetic degeneration. The protection is significant, and may 448 support the proposition for prospective human subject studies. after degeneration induction. Mice treated with PBS and exposed to 3,000-lux 480 light for 4 hours to induce degeneration exhibited a-and b-wave mean 481 amplitudes (red) that were statistically significantly diminished compared to those 482 of dim groups (blue and black). However, the mean ERG amplitudes of mice 483 undergoing retinal degeneration and treated with NR (green) were statistically 484 indistinguishable from those treated with PBS and exposed to bright light. **P < 485 0.01, ***P < 0.001, ****P < 0.0001 versus other groups by two-way ANOVA with 486 Mice treated with PBS and exposed to 3,000-lux light for 4 hours to induce degeneration exhibited a-and b-wave mean amplitudes (red) that were statistically significantly diminished compared to those of dim groups (blue and black). However, the mean ERG amplitudes of mice undergoing retinal degeneration and treated with NR (green) were statistically indistinguishable from those treated with PBS and exposed to bright light . **P < 0.01, ***P < 0.001, ****P < 0.0001 versus other groups by two-way ANOVA with Tukey's multiple comparisons non-parametric test. N=8-12 eyes per group. Error bars represent SEM. μ m from the optic nerve head. Photoreceptor thickness (C) and retinal thickness (D) from Balb/c mice at one week after degeneration induction. Mice treated with NR and exposed to 3,000-lux light for 4 hours (red bar) exhibited great losses in thickness of the photoreceptor and retina layers, whereas induced mice treated with NR (green bar) exhibited statistically significant preservation of layer thickness. ****p<0.0001 versus all other group means; one-way ANOVA with Tukey's multiple comparisons non-parametric test. N = 3-6 mice/group. Error bars represent SEM. Size marker size as shown in images . FIGURE 11. NR treatment increased retinal NAD+ levels in C57Bl/6J mice. Mice were IP injected with 1000 mg/kg NR or PBS for 5 consecutive days. Two hours after the last injection, they were sacrificed and retinas harvested. NADH and NAD(total) were assessed by colorimetric assay. Retinal NAD+ levels (A) and NAD+/NADH ratio (B) from mice treated with NR were statistically significantly increased compared to vehicle (PBS) treated group. **P<0.01 by Student t-test. N = 6 mouse retinas/ group. Error bars represent SEM. B A Figure S1 . NR treatment preserves nuclei of the outer nuclear layer in the LIRD mice. A week after toxic light exposure, mice were euthanized and ocular sections stained with hematoxylin and eosin (H&E). Representative H&E images of complete retina sections from each treatment group are shown. Panel A: Section from a PBS-treated mouse exposed to dim light shows unperturbed ONL across the span of the retina. Panel B: Section from a PBS-treated mouse with toxic light exposure shows extreme thinning in the central, superior (right side of section) ONL. Panel C: Section from a NR-treated mouse exposed to toxic light shows similar thickness ONL as that in control mouse.
Figure S2. NR treatment prevents increases TUNEL-positive cells following induction of LIRD.
A week after toxic light exposure the mice were euthanized and ocular sections stained for TUNEL (green) and DAPI (blue). Representative images of complete retina sections from each treatment group are shown. The right half of each section is dorsal/superior and the left half is ventral periphery/inferior. Panel A: Section from a PBS-treated mouse exposed to dim light shows little to no TUNEL-positive ONL nuclei across the span of the retina. Panel B: Section from a PBS-treated mouse with toxic light exposure shows numerous TUNEL-positive ONL nuclei in both superior and inferior halves. Panel C: Section from a NR-treated mouse exposed to toxic light shows much fewer TUNEL-positive ONL nuclei relative to PBS-treated mouse section.
